Open Access<p>Delayed remission following sequential infusion of humanized CD19- and CD22-modified CAR-T cells in a patient with relapsed/refractory acute lymphoblastic leukemia and prior exposure to murine-derived CD19-directed CAR-T cells</p>
Author(s) -
Fei Yang,
Jian Zhang,
Xinyou Zhang,
Meng-Li Tian,
Jingjing Wang,
Liqing Kang,
Huiying Qiu,
Depei Wu
Publication year - 2019
Publication title -
oncotargets and therapy
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.054
H-Index - 60
ISSN - 1178-6930
DOI - 10.2147/ott.s189103
Subject(s) - lymphoblast , cd19 , medicine , flow cytometry , refractory (planetary science) , cd22 , lymphoblastic leukemia , leukemia , saporin , immunology , bone marrow , cancer research , cell culture , biology , antibody , monoclonal antibody , immunotoxin , genetics , astrobiology
CD19-modified CAR-T cells greatly influence responses in patients with relapsed/refractory acute lymphoblastic leukemia (ALL). However, recurrence remains a challenge, and reinfusion of CAR-T cells is not always effective. Sequential infusion of humanized CD19-modified and CD22-modified CAR-T cells may overcome this issue and induce remission.